NORML

JANUARY 4, 2019

Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis. Pennsylvania.

Legislation 128

Legislation Clinical Trials Research and Development Access 128

The Cannigma

AUGUST 31, 2021

A 2018 research paper in the International Journal of Drug Policy analyzed in-depth interviews carried out with 24 Israeli physicians working in pain medicine, oncology, and family medicine, and found that “physicians discussed contrasting narratives of cananbi, presenting it as both a medicine and non-medicine.”

Education 101

Education Clinical Trials Medicine Policy 101

Cannabis Law Report

MAY 29, 2022

7] And cities around the country are beginning to decriminalize some psychedelics, with advocates for decriminalization citing the potential medical benefits. In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JUNE 10, 2021

Marijuana policies in the United States have become more permissive, motivating research on demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use. Marijuana policies in the United States (U.S.) Introduction.

Policy 59

Policy Safety Marijuana Data 59

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. Meanwhile, a decriminalization bill was defeated in the Virginia House this week. Click here to email your lawmakers in support of decriminalization. Virgin Islands.

Legislation 163

Legislation Decriminalization Access Therapy 163

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Veriheal

DECEMBER 21, 2022

Another section requires the Department of Health and Human Services (HHS) to look at the health benefits and risks of marijuana as well as policies that are inhibiting research into cannabis that’s grown in legal states and provide recommendations on overcoming those barriers.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

Canna Law Blog

NOVEMBER 6, 2021

Instead, qualifying evidence may come from adequate and well-controlled clinical trials. Phase I trials should be sufficient, and many have been completed using psilocybin. Rescheduling can help solve this problem by promoting larger trials. cities and the State of Oregon have decriminalized or legalized psilocybin.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Canna Law Blog

MARCH 4, 2020

Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine. Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ).

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

AUGUST 30, 2019

The National Institute on Drug Abuse published a grant notice to encourage research on the effects of changing US cannabis laws and policies on public health. This scandal reflects the ongoing debate in Kenya over the possible passage of legislation to decriminalize cannabis use. Medical/Health.

Banking 45

Banking Research and Development Legislation Programs 45

The Cannigma

MAY 7, 2021

Now, that’s going to matter significantly when as we advance clinical trials, as we advance product formulation as not just product formulation within pharma but all product formulation and that comes down to the initial process in relation to the supply chain of pretty hardcore standardization. MSO: Let’s pivot for a minute.

Supply Chain 120

Supply Chain Patients Access Hemp 120

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. There’s the one drug, one target, cannabis is multiple active ingredients and acts on multiple targets in the body.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map.

Law 74

Law Research and Development Therapy Treatment 74

SpeedWeed

SEPTEMBER 16, 2021

Many cities have decriminalized psychedelics, and the state of Oregon has decriminalized all drugs and is currently setting up a framework for administering psilocybin in a clinical setting. A clinical trial on MDMA is set to finish in 2022, which could lead to FDA approval. Their drug policies are good.

Education 86

Education Decriminalization Research and Development Clinical Trials 86

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

JULY 21, 2022

By decriminalizing cannabis at the federal level, the CAOA also ensures that state-legal cannabis businesses or those in adjacent industries will no longer be denied access to bank accounts or financial services simply because of their ties to cannabis.

Safety 52

Safety Legislation Clinical Trials Banking 52

Cannabis Law Report

OCTOBER 17, 2019

As more countries legalize or decriminalize the cultivation, manufacture, sale, and use of cannabis, companies across a variety of industries are looking for opportunities to capitalize on this emerging market. Several bills have been introduced in Congress in 2019 that call for legalizing or decriminalizing the substance.

Law 40

Law Seed-To-Sale Hemp Recreational 40

NORML

JANUARY 28, 2019

Presidents Barack Obama and Donald Trump have voiced support for state governments deciding their own policies. The National Center for Biotechnology Information has summarized a group of FDA approved randomized clinical trials, finding evidence for cannabis as medicine. So, in seven years why hasn’t Kentucky moved forward?

Data 188

Data Clinical Trials Chronic Pain Medicine 188

Cannabis Law Report

JUNE 30, 2019

Although the amendments represent an unprecedented level of support for pro-cannabis policies in the House, a similar level of support in the Republican-controlled Senate is unlikely. The Federal Aviation Administration issued a bulletin clarifying its cannabis and CBD policy for pilots.

Chronic Pain 40

Chronic Pain Legislation Treatment Programs 40

Cannabis Law Report

DECEMBER 30, 2019

After this historically successful year, we expect to see public and political support continue to increase in 2020 as more and more states implement sensible cannabis regulatory policies. “Never before in American history has marijuana policy advanced in Congress as far or as fast in one year as 2019. Erik Altieri.

Legislation 59

Legislation Patients Access Banking 59

Cannabis Law Report

JANUARY 14, 2020

Senior Policy Advisor, Diversion Control Division. The MORE Act would decriminalize marijuana and THC at the federal level by removing it from Schedule I of the Controlled Substances Act, which currently classifies it as an addictive drug that has no accepted medical use, akin to heroin. Drug Enforcement Administration.

Clinical Trials 69

Clinical Trials Programs Access DEA 69